Lifeward's ReWalk Personal Exoskeleton Now Covered by Aetna, Coverage Expands to Include Three of the Largest Medicare Advantage Insurers
Aetna joins Humana and United Healthcare in providing Medicare Advantage coverage for beneficiaries who meet medical necessity criteria for the ReWalk Personal Exoskeleton
Together, these three national Medicare Advantage insurers represent approximately 16 million beneficiaries across the United States
HUDSON, Mass. and YOKNEAM ILLIT, Israel, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology designed to transform the lives of people with physical limitations or disabilities, today announced that Aetna has issued a prior authorization for a Medicare Advantage beneficiary to obtain the ReWalk Personal Exoskeleton, recognizing the device as medically necessary for a qualifying individual living with spinal cord injury. With Aetna's decision, coverage for the ReWalk Personal Exoskeleton now spans three of the largest Medicare Advantage insurers, as UnitedHealthcare and Humana have also issued prior authorizations for qualified beneficiaries.
"Aetna's decision represents meaningful progress in expanding access to evidence-based advanced rehabilitation technology," said Mark Grant, CEO of Lifeward. "As leading Medicare Advantage insurers independently review the clinical evidence and reach consistent medical necessity determinations, it reinforces that exoskeleton-assisted walking serves as an appropriate therapeutic intervention for qualified individuals living with spinal cord injury."
The ReWalk Personal Exoskeleton System is an FDA-approved technology designed to enable individuals with spinal cord injury to achieve functional ambulation. Multiple peer-reviewed studies have demonstrated the system's benefits related to ambulation, musculoskeletal health, and cardiopulmonary function.
These recent prior authorization approvals carry significant meaning for patients and providers who have long advocated for broader access to exoskeletal rehabilitation technology. Among those benefiting from the expanded coverage landscape is a nurse living with thoracic spinal cord injury whose Medicare Advantage plan authorized a ReWalk Personal Exoskeleton.
"As a nurse for 15 years and someone who sustained a spinal cord injury in 2022, I understand both professionally and personally how life-changing this kind of technology can and will be for so many," the beneficiary said. "I've cared for patients navigating spinal cord injuries, and I live that reality every single day. Access to innovative mobility devices means more than movement; it means dignity, healing, and a renewed sense of independence. Having a favorable decision for my Aetna Advantage plan for this device is groundbreaking; it opens the door for others in our community to experience that same opportunity for progress and possibility."
With prior authorizations from three of the largest Medicare Advantage insurers, beneficiaries who qualify may now pursue access to the ReWalk Personal Exoskeleton. Lifeward continues to collaborate closely with insurers, clinicians, and rehabilitation professionals to integrate advanced rehabilitation technology as a critical element of spinal cord injury management.
About Lifeward
Lifeward designs, develops, and commercializes life-changing solutions that span the continuum of care in physical rehabilitation and recovery, delivering proven functional and health benefits in clinical settings as well as in the home and community. Our mission at Lifeward is to relentlessly drive innovation to change the lives of individuals with physical limitations or disabilities. We are committed to delivering groundbreaking solutions that empower individuals to do what they love. The Lifeward portfolio features innovative products including the ReWalk Exoskeleton, the AlterG Anti-Gravity systems, the ReStore Exo-Suit, and the MyoCycle FES Systems.
Founded in 2001, Lifeward has operations in the United States, Israel, and Germany. For more information on the Lifeward product portfolio, please visit GoLifeward.com.
ReWalk
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Jensen Huang's sudden resignation shrouded in suspicion: Did the White House secretly intervene? Is a return possible in the future?
Only a few days separated Jensen Huang’s strong support from the board last Sunday and his late-night resignation on Wednesday. Multiple reports of the Wednesday night Nvidia board meeting were co-authored by Washington-based journalists—who do not typically cover Nvidia—fueling rumors of "White House pressure and information leaks." Huang’s unique value lies in leveraging his personal reputation to secure the supply chain and drive the implementation of technological roadmaps, making him difficult to replace. Some analysts note that, drawing on examples such as Steve Jobs’ return to Apple, it is possible that Huang may come back in the future.

Gold recovers from YTD low, retakes $3,900; Fed hike bets and bullish USD to cap gains
Cerebras (CBRS.US) Cloud Business Soars, Masking Hardware Decline; OpenAI Supports Half of Cloud Revenue
Cerebras achieved record Q3 revenue, but hardware income dropped by nearly 30%, while cloud business accounted for two-thirds of total revenue. OpenAI contributed $72.4 million. The company raised its full-year guidance and expects Q4 to be close to breakeven.
